GM2 gangliosidosis
- E75.0 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
- The 2025 edition of ICD-10-CM E75.0 became effective on October 1, 2024.
- This is the American ICD-10-CM version of E75.0 – other international versions of ICD-10 E75.0 may differ.
The following code(s) above E75.0 contain annotation back-references
that may be applicable to E75.0:
- E00-E89 Endocrine, nutritional and metabolic diseases
- E70-E88 Metabolic disorders
- E75 Disorders of sphingolipid metabolism and other lipid storage disorders
Clinical Information
- A group of recessively inherited diseases characterized by the intralysosomal accumulation of g(m2) ganglioside in the neuronal cells. Subtypes include mutations of enzymes in the beta-n-acetylhexosaminidases system or g(m2) activator protein leading to disruption of normal degradation of gangliosides, a subclass of acidic glycosphingolipids.
Code History
- 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
- 2017 (effective 10/1/2016): No change
- 2018 (effective 10/1/2017): No change
- 2019 (effective 10/1/2018): No change
- 2020 (effective 10/1/2019): No change
- 2021 (effective 10/1/2020): No change
- 2022 (effective 10/1/2021): No change
- 2023 (effective 10/1/2022): No change
- 2024 (effective 10/1/2023): No change
- 2025 (effective 10/1/2024): No change
Code annotations containing back-references to E75.0:
- Type 1 Excludes: E78